Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma

By afschroeder • October 7, 2025

Sullivan RJ, Tsai KK, Pavlick AC, Buchbinder EI, Agarwala SS, Ribas A, Jansson J, Rossiter G, Olszanski AJ. Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma. J Cancer. 2025 Aug 11;16(13):3797-3809. doi: 10.7150/jca.117878. PMID: 41049010; PMCID: PMC12490977.

Tags: Checkpoint blockade, Combination immunotherapy, Hematology/Oncology, melanoma, Plozalizumab, Publications, Tovorafenib, Toxicities, vedolizumab

Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery

Silverstein JF, Smick A, Tsui E, Alomaja O, Johnson B, Tseng CH, Salani R, Slamon DJ, Chase DM, Konecny GE. Mirvetuximab Soravtansine Exposure and Incidence[...]

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3

Nooka AK, Strouse C, Larson SM, Lesokhin A, Varshavsky-Yanovsky A, Vesole DH, Koehne G, Soussou E, Sullivan ST, Cheng J, Raje N. Efficacy and safety[...]

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma

Piperno-Neumann S, Rutkowski P, Hassel JC, Butler MO, Schlaak M, Sullivan RJ, Dummer R, Kirkwood JM, Sacco JJ, Shoushtari AN, Piulats JM, Salama AKS, Orloff[...]